CVE-2026-56152: Incorrect Authorization (CWE-863) in Kibana can lead to unauthorized information disclosure via Accessing Func
CVE-2026-56152 is a medium-severity flaw (CVSS 5.3) affecting endpoint security. Below: why it ranks where it does, which versions are affected, what to do, and the exact commands.
Incorrect Authorization (CWE-863) in Kibana can lead to unauthorized information disclosure via Accessing Functionality Not Properly Constrained by ACLs (CAPEC-1). Under certain conditions, a low-privileged authenticated user can access response action data that they are not authorized to view.
Why this priority
- No elevated risk signals yet
A fixed release or distro patch exists.
Risk facts
| CVSS score | 5.3 (Medium) |
| Attack vector | Network (remote) |
| Attack complexity | High |
| Privileges needed | Low |
| User interaction | None |
| EPSS exploit chance | 0.3% (top 77%) |
| CISA exploited list | No |
| Weakness | CWE-863 |
| Published | 2026-07-01 |
| Last modified | 2026-10-25 |
Last updated 2026-10-25 · Sources: CVE Program, NVD, CISA KEV, EPSS and vendor advisories · How we score
Am I affected?
Timeline
- Published CVE record published
- Updated Record last modified
Scores and fixes here are computed automatically from those and other public sources. Confirm with the vendor advisory before changing production systems.
Quick answers
How do I fix CVE-2026-56152?
endpoint security: upgrade to 8.19.13, 9.2.7, 9.3.2. Exact commands for each OS are on this page.
Is CVE-2026-56152 being exploited?
CVE-2026-56152 is not on the CISA Known Exploited Vulnerabilities list at the time of the last update. Check again, as this can change.
What does CVE-2026-56152 affect?
CVE-2026-56152 affects endpoint security. Severity is medium (CVSS 5.3). Incorrect Authorization (CWE-863) in Kibana can lead to unauthorized information disclosure via Accessing Functionality Not Properly Constrained by ACLs (CAPEC-1). Under certain conditions, a low-privileged authenticated user can access res
How urgent is CVE-2026-56152?
Priority 24/100. No elevated risk signals yet.